News | Cardiovascular Clinical Studies | April 20, 2023

Graphene ‘Tattoo’ Treats Cardiac Arrhythmia with Light

First graphene-based cardiac implant senses irregularities, then stimulates the heart 

First graphene-based cardiac implant senses irregularities, then stimulates the heart

Graphene implant on tattoo paper. Image courtesy of Ning Liu/University of Texas at Austin 


April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed the first cardiac implant made from graphene, a two-dimensional super material with ultra-strong, lightweight and conductive properties. 

Similar in appearance to a child’s temporary tattoo, the new graphene “tattoo” implant is thinner than a single strand of hair yet still functions like a classical pacemaker. But unlike current pacemakers and implanted defibrillators, which require hard, rigid materials that are mechanically incompatible with the body, the new device softly melds to the heart to simultaneously sense and treat irregular heartbeats. The implant is thin and flexible enough to conform to the heart’s delicate contours as well as stretchy and strong enough to withstand the dynamic motions of a beating heart. 

After implanting the device into a rat model, the researchers demonstrated that the graphene tattoo could successfully sense irregular heart rhythms and then deliver electrical stimulation through a series of pulses without constraining or altering the heart’s natural motions. Even better: The technology also is optically transparent, allowing the researchers to use an external source of optical light to record and stimulate the heart through the device. 

The study will be published on Thursday (April 20) in the journal Advanced Materials. It marks the thinnest known cardiac implant to date. 

“One of the challenges for current pacemakers and defibrillators is that they are difficult to affix onto the surface of the heart,” said Northwestern’s Igor Efimov, the study’s senior author. “Defibrillator electrodes, for example, are essentially coils made of very thick wires. These wires are not flexible, and they break. Rigid interfaces with soft tissues, like the heart, can cause various complications. By contrast, our soft, flexible device is not only unobtrusive but also intimately and seamlessly conforms directly onto the heart to deliver more precise measurements.” 

An experimental cardiologist, Efimov is a professor of biomedical engineering at Northwestern’s McCormick School of Engineering and professor of medicine at Northwestern University Feinberg School of Medicine. He co-led the study with Dmitry Kireev, a research associate at UT. Zexu Lin, a Ph.D. candidate in Efimov’s laboratory, is the paper’s first author. 

Miracle Material 

Known as cardiac arrhythmias, heart rhythm disorders occur when the heart beats either too quickly or too slowly. While some cases of arrhythmia are not serious, many cases can lead to heart failure, stroke and even sudden death. In fact, complications related to arrythmia claim about 300,000 lives annually in the United States. Physicians commonly treat arrhythmia with implantable pacemakers and defibrillators that detect abnormal heartbeats and then correct rhythm with electrical stimulation. While these devices are lifesaving, their rigid nature may constrain the heart’s natural motions, injure soft tissues, cause temporary discomfort and induce complications, such as painful swelling, perforations, blood clots, infection and more. 

With these challenges in mind, Efimov and his team sought to develop a bio-compatible device ideal for conforming to soft, dynamic tissues. After reviewing multiple materials, the researchers settled on graphene, an atomically thin form of carbon. With its ultra-strong, lightweight structure and superior conductivity, graphene has potential for many applications in high-performance electronics, high-strength materials and energy devices. 

“For bio-compatibility reasons, graphene is particularly attractive,” Efimov said. “Carbon is the basis of life, so it’s a safe material that is already used in different clinical applications. It also is flexible and soft, which works well as an interface between electronics and a soft, mechanically active organ.” 

Hitting a Beating Target 

At UT, study co-authors Dimitry Kireev and Deji Akinwande were already developing graphene electronic tattoos (GETs) with sensing capabilities. Flexible and weightless, their team’s e-tattoos adhere to the skin to continuously monitor the body’s vital signs, including blood pressure and the electrical activity of the brain, heart and muscles. 

But, while the e-tattoos work well on the skin’s surface, Efimov’s team needed to investigate new methods to use these devices inside the body — directly onto the surface of the heart. 

“It’s a completely different application scheme,” Efimov said. “Skin is relatively dry and easily accessible. Obviously, the heart is inside the chest, so it’s difficult to access and in a wet environment.” 

The researchers developed an entirely new technique to encase the graphene tattoo and adhere it to the surface of a beating heart. First, they encapsulated the graphene inside a flexible, elastic silicone membrane — with a hole punched in it to give access to the interior graphene electrode. Then, they gently placed gold tape (with a thickness of 10 microns) onto the encapsulating layer to serve as an electrical interconnect between the graphene and the external electronics used to measure and stimulate the heart. Finally, they placed it onto the heart. The entire thickness of all layers together measures about 100 microns in total. 

The resulting device was stable for 60 days on an actively beating heart at body temperature, which is comparable to the duration of temporary pacemakers used as bridges to permanent pacemakers or rhythm management after surgery or other therapies. 

Optical Opportunities 

Leveraging the device’s transparent nature, Efimov and his team performed optocardiography — using light to track and modulate heart rhythm — in the animal study. Not only does this offer a new way to diagnose and treat heart ailments, the approach also opens new possibilities for optogenetics, a method to control and monitor single cells with light.  

While electrical stimulation can correct a heart’s abnormal rhythm, optical stimulation is more precise. With light, researchers can track specific enzymes as well as interrogate specific heart, muscle or nerve cells. 

“We can essentially combine electrical and optical functions into one biointerface,” Efimov said. “Because graphene is optically transparent, we can actually read through it, which gives us a much higher density of readout.” 

The study, “Graphene biointerface for cardiac arrhythmia diagnosis and treatment,” was supported by the National Institutes of Health (grant numbers R21-HL152324, 3OT2OD023848 and R01-HL141470), the Leducq Foundation (RHYTHM grant), the Office of Naval Research (grant number N00014-18-1-2706) and the Temple Foundation.  

For more information: www.northwestern.edu 


Related Content

News | Heart Failure

May 22, 2024 — New research from The Cooper Institute and partners at University of Texas (UT) Southwestern Medical ...

Home May 22, 2024
Home
News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
Subscribe Now